| 2025-12-17 |
详情>>
内部人交易：
Anzalone Christopher Richard共交易4笔
|
| 2025-12-11 |
详情>>
股本变动：
变动后总股本13587.97万股
|
| 2025-11-25 |
详情>>
业绩披露：
2025年年报每股收益-0.01美元,归母净利润-163.1万美元,同比去年增长99.73%
|
| 2025-11-25 |
财报披露：
美东时间 2025-11-25 盘后发布财报
|
| 2025-11-19 |
复牌提示：
2025-11-18 11:06:46 停牌，复牌日期 2025-11-18 12:15:00
|
| 2025-08-07 |
详情>>
业绩披露：
2025年三季报(累计)每股收益0.17美元,归母净利润2211.90万美元,同比去年增长105.16%
|
| 2025-05-12 |
详情>>
业绩披露：
2025年中报每股收益1.53美元,归母净利润1.97亿美元,同比去年增长176.45%
|
| 2025-02-10 |
详情>>
业绩披露：
2025年一季报每股收益-1.39美元,归母净利润-1.73亿美元,同比去年增长-30.27%
|
| 2025-01-29 |
股东大会：
将于2025-03-12召开股东大会
会议内容 ▼▲
- 1.To elect the eight directors named in the Proxy Statement to serve as members of the Company’s Board of Directors until the next Annual Meeting or until their successors are elected;
2.To conduct an advisory (non-binding) vote to approve executive compensation;
3.To conduct an advisory (non-binding) vote on the frequency of future advisory votes to approve executive compensation;
4.To ratify the selection of KPMG LLP as independent auditors of the Company for the fiscal year ending September 30, 2025;
5.To transact any other matters that may properly come before the Annual Meeting or any adjournments or postponements thereof.
|
| 2024-11-26 |
详情>>
业绩披露：
2022年年报每股收益-1.67美元,归母净利润-1.76亿美元,同比去年增长-25%
|
| 2024-11-26 |
详情>>
业绩披露：
2024年年报每股收益-5美元,归母净利润-5.99亿美元,同比去年增长-192.04%
|
| 2024-08-08 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-3.63美元,归母净利润-4.29亿美元,同比去年增长-348.72%
|
| 2024-08-08 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.9美元,归母净利润-9559.6万美元,同比去年增长-5.57%
|
| 2024-05-09 |
详情>>
业绩披露：
2024年中报每股收益-2.24美元,归母净利润-2.58亿美元,同比去年增长-3612.44%
|
| 2024-02-06 |
详情>>
业绩披露：
2024年一季报每股收益-1.24美元,归母净利润-1.33亿美元,同比去年增长-221.51%
|
| 2024-01-26 |
股东大会：
将于2024-03-14召开股东大会
会议内容 ▼▲
- 1.To elect the seven directors named in the Proxy Statement to serve as members of the Company’s Board of Directors until the next Annual Meeting or until their successors are elected;
2.To conduct an advisory (non-binding) vote to approve executive compensation;
3.To ratify the selection of KPMG LLP as independent auditors of the Company for the fiscal year ending September 30, 2024;
4.To transact any other matters that may properly come before the Annual Meeting or any adjournments or postponements thereof.
|
| 2023-11-29 |
详情>>
业绩披露：
2023年年报每股收益-1.92美元,归母净利润-2.05亿美元,同比去年增长-16.59%
|
| 2023-01-30 |
股东大会：
将于2023-03-16召开股东大会
会议内容 ▼▲
- 1.To elect the eight directors named in the Proxy Statement to serve as members of the Company’s Board of Directors until the next Annual Meeting or until their successors are elected;
2.To conduct an advisory (non-binding) vote to approve executive compensation;
3.To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock;
4.To ratify the selection of Rose, Snyder & Jacobs LLP as independent auditors of the Company for the fiscal year ending September 30, 2023;
5.To transact any other matters that may properly come before the Annual Meeting or any adjournments or postponements thereof.
|
| 2022-01-26 |
股东大会：
将于2022-03-17召开股东大会
会议内容 ▼▲
- 1.To elect the seven directors named in the Proxy Statement to serve as members of the Company’s Board of Directors until the next Annual Meeting or until their successors are elected;
2.To conduct an advisory (non-binding) vote to approve executive compensation;
3.To approve the Arrowhead Pharmaceuticals, Inc. Non-Employee Director Compensation Plan;
4.To ratify the selection of Rose, Snyder & Jacobs LLP as independent auditors of the Company for the fiscal year ending September 30, 2022;
5.To transact any other matters that may properly come before the Annual Meeting or any adjournments or postponements thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-01-28 |
股东大会：
将于2021-03-18召开股东大会
会议内容 ▼▲
- 1.To elect the seven directors named in the Proxy Statement to serve as members of the Company’s Board of Directors until the next Annual Meeting or until their successors are elected;
2.To conduct an advisory (non-binding) vote to approve executive compensation;
3.To approve the Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan;
4.To ratify the selection of Rose, Snyder & Jacobs LLP as independent auditors of the Company for the fiscal year ending September 30, 2021;
|
| 2020-01-28 |
股东大会：
将于2020-03-19召开股东大会
会议内容 ▼▲
- 1.To elect the six directors named in the Proxy Statement to serve as members of the Company’s Board of Directors until the next Annual Meeting or until their successors are elected;
2.To conduct an advisory (non-binding) vote to approve executive compensation;
3.To approve an amendment to the Company’s Amended and Restated By-Laws to implement a majority vote standard in uncontested elections of directors;
4.To ratify the selection of Rose, Snyder & Jacobs LLP as independent auditors of the Company for the fiscal year ending September 30, 2020;
|
| 2019-01-25 |
股东大会：
将于2019-03-14召开股东大会
会议内容 ▼▲
- 1.To elect the five directors named in the Proxy Statement to serve as members of the Company’s Board of Directors until the next Annual Meeting or until their successors are elected;
2.To conduct an advisory (non-binding) vote to approve executive compensation;
3.To conduct an advisory (non-binding) vote on the frequency of future advisory votes on executive compensation;
4.To ratify the selection of Rose, Snyder & Jacobs LLP as independent auditors of the Company for the fiscal year ending September 30, 2019;
|
| 2018-01-25 |
股东大会：
将于2018-03-16召开股东大会
会议内容 ▼▲
- 1.To elect the six directors named in the Proxy Statement to serve as members of the Company’s Board of Directors until the next Annual Meeting or until their successors are elected;
2.To conduct an advisory (non-binding) vote to approve executive compensation;
3.To ratify the selection of Rose, Snyder & Jacobs LLP as independent auditors of the Company for the fiscal year ending September 30, 2018;
|
| 2017-02-01 |
股东大会：
将于2017-03-21召开股东大会
会议内容 ▼▲
- 1.To elect the five directors named in the Proxy Statement to serve as members of the Company’s Board of Directors until the next Annual Meeting or until their successors are elected;
2.To conduct an advisory (non-binding) vote on executive compensation;
3.To ratify the selection of Rose, Snyder & Jacobs LLP as independent auditors of the Company for the fiscal year ending September 30, 2017;
|
| 2016-01-19 |
股东大会：
将于2016-03-08召开股东大会
会议内容 ▼▲
- 1.To elect the five directors named in the Proxy Statement to serve as members of the Company’s Board of Directors until the next Annual Meeting or until their successors are elected;
2.To conduct an advisory (non-binding) vote on executive compensation;
3.To ratify the selection of Rose, Snyder & Jacobs LLP as independent auditors of the Company for the fiscal year ending September 30, 2016;
|